Evonik Industries has announced that it is significantly expanding its global isophorone (IP) and isophorone diamine (IPD) capacities by funding an investment of more than €100M in Shanghai, China. The new production plants will be completed in Q1, 2014 and will increase the total capacities of IP and IPD significantly.
"Our aim in building the plants in Shanghai – at the company’s existing multi-user site – is to supply our Asian customers with the same high-quality products they are used to from our plants in Europe and the USA, now from a plant in the region," says Gerd Brand, Senior Vice President and Head of Crosslinkers Business Line
